Nxera Forms Metabolic Advisory Council To Advance Obesity And Metabolic Pipeline

Nxera Pharma Co., Ltd has announced the formation of a Metabolic Advisory Council made up of globally recognised experts to support the scientific, clinical, and strategic development of its growing pipeline in obesity and metabolic disorders. The Council is intended to guide Nxera as it advances next-generation therapies addressing some of the most complex unmet needs in metabolic disease.

The founding members of the Council include Professor Sir Stephen O’Rahilly of the University of Cambridge, a pioneer in the genetic and molecular understanding of obesity and diabetes; Professor Tricia Tan of Imperial College London, a leading clinician-scientist in metabolic medicine and endocrinology; and Dr. Mads Tang-Christensen, a former Novo Nordisk executive and biotech innovator with extensive experience in obesity biology and first-in-class therapeutic development.

Dr. Patrik Foerch, Chief Scientific Officer and President of Nxera Pharma UK, commented: “The formation of the Metabolic Advisory Council marks an important milestone in our ambition to deliver best-in-class therapies for obesity and metabolic disorders. Sir Stephen, Professor Tan, and Dr TangChristensen each bring exceptional expertise that will directly influence our scientific strategy and clinical 2 3 development plans. Their collective insight will enable us to accelerate the progression of our next-generation metabolic programs, ensuring our pipeline is shaped by the highest standards of scientific rigour and real-world patient need.”

Nxera’s advisory initiative follows the Company’s August 2025 announcement of a broad proprietary pipeline focused on next-generation, best-in-class treatments for obesity and metabolic disorders. The pipeline is designed to meet evolving patient needs, including long-term weight maintenance through convenient oral therapies, management of metabolic and cardiovascular co-morbidities, and treatment of populations that are difficult to manage with current options.

The Company’s approach emphasizes improved tolerability, reduced side effects, and differentiated mechanisms of action, enabled by its proprietary NxWave™ structure-based GPCR design platform. With guidance from the Metabolic Advisory Council, Nxera aims to strengthen its scientific strategy and accelerate the progression of its innovative metabolic assets toward clinical development.